Professional
Added to YB: 2024-06-05
Pitch date: 2024-06-05
ALVR [bullish]
AlloVir, Inc.
-43.96%
current return
Author Info
ToffCap are full-time fund managers finding undervalued opportunities and a reason why the price should (start to) move in the right direction. Sign up for their newsletter.
Company Info
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases.
Market Cap
$49.3M
Pitch Price
$17.51
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.92
P/E
-0.49
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
$ALVR setup for acquisition?
$ALVR: Speculative biotech play. Stock down big, facing delisting. $165M cash, 95% workforce cut, assessing strategic options. Insider bonuses hint at potential acquisition. High risk, high reward opportunity.
Read full article (1 min)